english.prescrire.org > Prescrire International > N°164 - October 2015

n°164

October 2015

Issue Contents
Editorial

Free  The imaging mirage

p.228
Poorly informative clinical trials

New Products


Naltrexone + bupropion (Mysimba°)

p.229-233
Too risky for only modest weight loss

What a waste!

p.232
Editor's opinion

INN common stem: -ciguat

p.233

Free  Regorafenib (Stivarga°) and gastrointestinal stromal tumours after treatment failure

p.234
Radiological improvement but major adverse effects

Defibrotide (Defitelio°)

p.235
An antithrombotic drug with too many uncertainties in hepatic veno-occlusive disease

Adverse Effects


Treatment of childhood cancers: late effects

p.236-239
Monitoring into adulthood is essential

HPV vaccines and pregnancy (continued)

p.239-240
No risks identified

High-strength venlafaxine: best avoided

p.240
Marketing authorisation unacceptable whatever the dosage

Reviews


Hypothyroidism in adults

p.241-246
Levothyroxine if warranted by clinical and laboratory findings, not for simple TSH elevation

Hypothyroidism in adults: treat symptomatic patients

p.245
Prescrire's advice

Lyme disease

p.247-249
Recognising and treating erythema migrans

Tick bites: monitor closely, without routine antibiotic prophylaxis

p.249

Outlook


Drug-induced iatrogenesis: medication safety in a nursing home for the elderly

p.250
Limiting possible sources of error

Free  Exorbitant drug prices harm research

p.251
Cancer drugs are a prominent example

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe